Biotech Fine Chemical France
- Founded in: 2016
- Number of employees: 3
- Country: France
- Investors: Co-Founders
- Market: Fine Chemicals, phosphorylated compounds and API's
- Website: -
Which input provides your business model/core technology towards a bio-based economy?
Current methods to produce our compounds rely on chemical synthesis which are costly and toxic.
BFC breakthrough technology utilises Bio-production to do synthesise and bring down the cost and toxicity, rather than by chemical synthesis from non-renewable material.
Which market/clients do you address and which short-term/long-term goals do you have?
Our compounds and derivatives are used in many industries such as cosmetics, textiles, laboratory research, drug development and decontamination. Our first goal is to become the 1st supplier of phosphorylated compounds and derivatives of the pharmaceutical industry.
What makes your approach unique compared to other stakeholders in the field?
BFC will use a unique own developed bio-production strategy (BFC exclusive Patent), to produce a platform molecule through a genetically engineered bacteria. This solution will bring many compounds to a low market price/high margin and open attractive markets.
You can meet Biotech Fine Chemical France in Toulouse at the START-UP VILLAGE @EFIB on 17-18 October.